Viracta Therapeutics, a clinical-stage biotech company developing therapies to treat viral-associated cancers and other diseases, announced Thursday it appointed Dan Chevallard as its chief financial officer. Chevallard was most recently CFO at Regulus Therapeutics (NASDAQ: [[ticker:RGLS]]), another biotech company headquartered in San Diego.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
